Inquiry Basket
CAS No.:
Cat No.: BADC-02030
4.5 
Mirvetuximab-MMAE is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against FOLR1 and the tubulin inhibitor monomethyl auristatin E (MMAE). Mirvetuximab-MMAE can be used in the research of FRα-positive cancers.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Mirvetuximab-MMAE
Required fields are marked with *
Mirvetuximab-MMAE
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
